Monte Rosa Therapeutics

Monte Rosa Therapeutics

  • Founded: 2018
  • Location: Basel , Switzerland
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Multiple cancers
  • Drug types: ONC, IMM, GEN, HEM
  • Lead product: MRT-2359
  • Product link:
  • Funding: $223M IPO Jun 2021; $95M C Mar 2021; $96M B Sep 2020; $32.5M May 2020
  • Investors: Versant Ventures

job board

Short description:

Small molecule cancer drugs that modulate protein degradation pathways

Drug notes:

Undisclosed Clin0 autoimmune disease; 4 undisclosed programs RD inflammatory diseases, multiple cancers, sickle cell disease, B-thalassemia, undisclosed

Long description:

Monte Rosa Therapeutics is a biopharmaceutical company in Boston, MA, developing a new class of drugs called molecular glue degraders (MGDs) to fight cancer, autoimmune diseases, and inflammatory diseases. MGDs utilize the body's natural protein degradation pathways, including the ubiquitin-proteasome system, to eliminate therapeutically relevant proteins. MGDs bind to ubiquitin ligases complementary to the target protein, to tag the protein for degradation via the proteasome. These therapies have the potential to eliminate proteins considered to be “undruggable.” Their platform, called QuEEN (Quantitative and Engineered Elimination of Neosubstrates), allows the rapid identification of protein targets and design of MGD drug candidates.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy